High-Sensitivity and Trace-Amount Specimen Electrochemical Sensors for Exploring the Levels of β-Amyloid in Human Blood and Tears
Authors:
- 28 May 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 93 (22) , 8099-8106
Abstract
As the occurrence of Alzheimer’s disease (AD) has increased, the detection and treatment of AD have become global social issues. Effective early detection and wide-range screening of AD allow patients to gain early control and delay brain degeneration. For these reasons, we choose electrochemical sensors to complete the detection task. Although bio-electrochemical technology for antibody and antigen sensing is not a new technology, considering the scarcity of tear samples for dementia and since the existing AD detection techniques are highly invasive and expensive for subjects, we have to use the traditional detection techniques for the early screening of Alzheimer’s disease via trace-amount specimens. An AD-related protein in the eye is thought to be an important biomarker for early detection. To carry out detection using tear samples as a test specimens, a tear collection device was developed in this study that extracted 10 μL of tear fluid from a tear Schirmer strip. In this research, we distinguished healthy people in different age groups and detect Aβ in both tear and blood samples. We developed a biosensor, which could detect Aβ in tear specimen from 1 to 100 pg/mL. Also, this biosensor is inexpensive, disposable, and easy to use. In our result, the concentration of Aβ in tears was approximately 10 times more than that in blood. This study demonstrates the feasibility and prospects of future screening for AD-associated biomarkers by a dynamic comparison between blood and tears.Keywords
Funding Information
- National Taiwan University Hospital (NTUHHCB 107-HCH061)
- Ministry of Science and Technology, Taiwan (MOST 105-2221-E-009-093)
This publication has 37 references indexed in Scilit:
- NIA‐AA Research Framework: Toward a biological definition of Alzheimer's diseaseAlzheimer's & Dementia, 2018
- Amyloid-Beta: A Crucial Factor in Alzheimer's DiseaseMedical Principles and Practice, 2014
- Alzheimer disease immunotherapeutics: Then and nowHuman Vaccines & Immunotherapeutics, 2014
- N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s DiseaseCurrent Alzheimer Research, 2012
- Fluid Biomarkers in Alzheimer DiseaseCold Spring Harbor Perspectives in Medicine, 2012
- Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal FluidBiological Psychiatry, 2009
- Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice GuidelineAnnals of Internal Medicine, 2008
- Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humansAnnals of Neurology, 2006
- Tau phosphorylation in Alzheimer's disease: pathogen or protector?Trends in Molecular Medicine, 2005
- Alzheimer's disease is a degenerative disorderNeurobiology of Aging, 1989